Drugs / Dirozalkib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05586568 | Nov 2022 → Apr 2023 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dirozalkib | “Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib).” PMID 41348226 ↗ Dec 2025 |
| Action | Inhibit | “ALK tyrosine kinase inhibitor” PMID 41348226 ↗ Dec 2025 |
| Route | Oral | “Participants received a single oral dose of 500 mg Dirozalkib on Day 1 and 16.” PMID 41348226 ↗ Dec 2025 |
| Target | ALK | “ALK tyrosine kinase inhibitor” PMID 41348226 ↗ Dec 2025 |